Bausch Health (BHC) is expected to post Q1 revenue of $2.24 billion, shy of the $2.29 billion estimate of analysts polled by FactSet, RBC Capital Markets said in an earnings preview Monday.
RBC analysts also said they expect the pharmaceutical company to report Q1 adjusted EBITDA of $720 million while analysts surveyed by FactSet expect $769.8 million.
The investment firm said it revised its Q1 estimates due to foreign exchange movements and updated prescription data. Regarding tariffs, RBC analysts said they plan to seek updated comments from management on the potential impact to the company. Previously, Bausch Health's management said they were forecasting an impact of less than $500 million to cash flow under a 25% tariff rate.
Bausch Health is due to report Q1 results after the close on April 30.
RBC cut its price target to $8.50 from $9 and kept a sector perform rating on the stock.
Price: 5.09, Change: -0.25, Percent Change: -4.60
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。